


FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N
CMK		WO 95/19769	7/27/1995	Amira, Inc.	

Examiner Signature		Date Considered	4/30/03
-----------------------	---	--------------------	---------

Customer No. 000027683

U.S. DEPARTMENT OF COMMERCE
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)



Sheet 1 of 9

ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
CHK	3 4 7 8 1 4 6	11/1969	Balassa	424	548	
	3 9 6 6 9 0 8	06/1976	Balassa	424	548	
	Re. 2 8 0 9 3	07/1974	Balassa	424	548	
	4 0 2 0 1 5 8	04/1977	Ashmead et al.	424	177	
	4 0 4 2 4 5 7	08/1977	Kuettner et al.	424	548	
	4 1 0 3 0 0 3	07/1978	Ashmead	424	177	
	4 1 6 9 7 1 7	10/1979	Ashmead	71	89	
	4 2 1 2 8 5 7	07/1980	Balassa et al.	424	548	
	4 2 1 6 1 4 3	08/1980	Ashmead	260	113	
	4 2 4 3 5 8 2	01/1981	Spilburg et al.	530	395	
	4 3 5 0 6 8 2	09/1982	Balassa	424	64	
	4 3 5 6 2 6 1	10/1982	Kuettner	435	70.2	
	4 4 4 4 7 5 2	04/1984	Prudden	424	548	
	4 4 5 6 5 8 9	06/1984	Holman et al.	424	548	
	4 4 6 9 6 7 6	09/1984	Hecmati	424	548	
	4 4 7 3 5 5 1	09/1984	Schinitsky	424	548	
	4 5 9 9 1 5 2	07/1986	Ashmead	204	72	
	4 6 5 6 1 3 7	04/1987	Balassa	435	267	
	4 7 4 6 7 2 9	05/1988	Kuettner et al.	530	353	
	4 7 4 9 5 2 2	06/1988	Kamarei	563	--	
	4 8 2 2 6 0 7	04/1989	Balassa et al.	424	548	
	4 8 3 0 7 1 6	12/1999	Ashmead	205	457	
CHK	4 8 6 3 8 9 8	09/1989	Ashmead et al.	514	6	

EXAMINER

CHK

DATE CONSIDERED

4/30/02

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

(Use several sheets if necessary)



APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

Sheet 2 of 9

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
CMK	5 0 7 5 1 1 2	12/1991	Lane	42	434	
	5 1 6 2 3 6 9	11/1992	Ashmead et al.	514	492	
	5 1 6 4 3 6 7	11/1992	Pickart	514	6	
	5 2 9 2 7 2 9	03/1994	Ashmead	514	168	
	5 3 8 2 4 3 1	01/1995	Pickart	424	401	
	5 5 9 6 0 1 6	01/1997	Ashmead et al.	514	492	
	5 6 1 4 5 5 3	03/1997	Ashmead et al.	514	505	
	5 6 1 8 9 2 5	04/1997	Dupont et al.	530	400	
	5 6 9 6 0 9 2	12/1997	Patierno et al.	514	21	
	5 8 4 3 9 2 0	12/1998	Weisz			
	5 8 4 6 5 6 2	12/1998	Yanai et al.	424	451	
	5 8 8 8 5 5 3	03/1999	Grant et al.	424	655	
	5 9 0 2 7 9 0	05/1999	Green et al.	514	19	
	5 9 8 5 8 3 9	11/1999	Dupont et al.	514	21	
	6 0 2 5 3 3 4	02/2000	Dupont et al.	512	21	
	6 0 2 8 1 1 8	02/2000	Dupont et al.	514	863	
	6 1 1 4 3 7 9	09/2000	Wheelwright et al.	514	492	
	6 1 6 6 0 7 1	12/2000	Ashmead et al.	514	494	
	6 1 6 8 8 0 7	01/2001	Dupont et al.			
CMK	6 2 2 5 2 8 4	05/2001	Albert et al.	514	11	

EXAMINER

OKL

DATE CONSIDERED


4/30/03

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

(Use several sheets if necessary)

Sheet 3 of 9



014985-0012-72648

09/879,660

FILING DATE: June 12, 2001

GROUP:

[illegible]

DATE CONSIDERED

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

Sheet 4 of 9



ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CYK	Arnett, F. C. et al. (1988), <i>Arthritis & Rheumatism</i> , 31(3): 315-324.
	Auerbach, W. et al., "Angiogenesis Inhibition: A Review," 1999, <i>Pharmac. Ther.</i> 1994; 63:265-311
	Bhairi, S. M., "Detergents: A Guide to the Properties and Uses of Detergents in Biological Systems," Calbiochem-Novabiochem Corporation (1997), p. 39.
	Bischoff, J., "Approaches to studying cell adhesion molecules in angiogenesis," <i>Trend Cell Biol.</i> , 1995, 5:69-74
	Blood, Christine H. et al., "Tumor interactions with the vasculature: angiogenesis and tumor metastasis," <i>Biochimica et Biophysica Acta</i> , 1032: 89-118 (1990).
	Brem, H. et al., 1975, "Inhibition of Tumor Angiogenesis Mediated by Cartilage," <i>J. Experimental Medicine</i> , Vol. 141, pp. 427-439.
	Brem, Steven, "Angiogenesis and Cancer Control: From Concept to Therapeutic Trial," <i>JMCC</i> 6(5): 436-458 (1999).
	Brodt, P., "Characterization of Two Highly Metastatic Variants of Lewis Lung Carcinoma with Different Organ Specificity," <i>Cancer Research</i> , Vol. 46:2442-2448 (1986).
	Brooks, P.C., "Cell adhesion molecules in angiogenesis," <i>Cancer Metastasis Rev.</i> , 1996, 15:187-194
	Brooks, P.C., "Role of Integrins in Angiogenesis," <i>Eur. J. Cancer</i> , 1996, 32A:2423-9
	Brown, C. W. and S. M. Donahue, "Searching a UV-Visible Spectral Library," <i>Applied Spectroscopy</i> , Vol. 42(2): 347-352 (1988).
	Burdick & Jackson, "High Purity Solvent Guide," 2nd Ed., Burdick & Jackson Laboratories, Inc., pages 128-137.
	Bussolino, F. et al., "Role of Soluble Mediators in Angiogenesis," <i>Eur. J. Cancer</i> , 1996, 32A:2401-12
	Chabot-Fletcher, M. et al. (1994), "Interleukin-8 Production is Regulated by Protein Kinase C in Human Keratinocytes," <i>The Journal of Investigative Dermatology</i> , 103(4): 509-515.
	Davis, Paul F., Yi He, Richard H. Furneaux, Peter S. Johnston, Beate M. Ruger and George C. Slim, "Inhibition of Angiogenesis by Oral Ingestion of Powdered Shark Cartilage in a Rat Model," <i>Microvascular Research</i> , Vol. 54 (1997), p. 178-182.
	Davis-Smyth, Terri et al., "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade," <i>The EMBO Journal</i> 15:18, 4919-4927 (1996).
	Dupont, Eric et al., "Antiangiogenic Properties of a Novel Shark Cartilage Extract: Potential Role in the Treatment of Psoriasis," <i>Journal of Cutaneous Medicine and Surgery</i> , 2:3, 146-152 (1998).
	Dvorak, H. F. et al., "Vascular Permeability Factor/Vascular Endothelial Growth Factor and the Significance of Microvascular Hyperpermeability in Angiogenesis," p. 98-132.
	Elias, P.M. (1993), "Epidermal Lipids, Barrier Function, and Desquamation," <i>J. Invest. Dermatol.</i> 80: 044s-049s.
	Fan, Tai-Ping D., "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Angiogenesis Review</i> , 16, 57-66 (February 1995)
	Ferrara, N., "Missing link in angiogenesis," <i>Nature</i> , 1995, 376-467
CYK	Ferrara, N. et al., "The Biology of Vascular Endothelial Growth Factor," <i>Endocrine Rev.</i> , 1997, 18:4-25

EXAMINER

DATE CONSIDERED


EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

Sheet 5 of 9



ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CHK	/	Folkman, Judah and Michael Klagsbrun, "Angiogenic Factors," <i>Science</i> , Vol. 235, pp. 442-446.
	/	Form, D. et al., "Endothelial Cell Proliferation during Angiogenesis," <i>J. Cell Physiol.</i> , 1992, 152:196-205
	/	Ghosh, AK et al., "Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats," <i>J Pharmacol Exp Ther</i> , 295(2):802-9 (Nov. 2000).
	/	Griffioen, Arjan W. et al., "Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation," <i>Pharmacological Reviews</i> , 52:2, 237-268 (2000).
	/	Grove, G. L. (1994), "Age-Related Differences in Healing of Superficial Skin Wounds in Humans" in <i>The effects of aging in oral mucosa and skin</i> . ed. Squier & Hill CRC Press, pp. 121-127.
	/	Hamada, J. et al., "Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis," <i>Br. J. Cancer</i> , 1992, 66:349-354
	/	Hanahan, Douglas et al., "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis," <i>Cell</i> , 86: 353-364 (August 1996).
	/	Hanson et al., "A Specific Immunoassay for Monitoring Human Bone Resorption: Quantitation of Type I Collagen Cross-linked N-Telopeptides in Urine," <i>J. Bone & Min. Res.</i> , 1992, 7:1251-1258
	/	Hu, GF, "Copper stimulates proliferation of human endothelial cells under culture," <i>J Cell Biochem</i> , 69(3):326-35 (June 1998).
	/	Ingber, "Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy," <i>Sem. Cancer Biol.</i> , 1992, 3:57-63
	/	Jackson, Jeffrey R. et al., "The codependence of angiogenesis and chronic inflammation," <i>FASEB J.</i> 11, 457-465 (1997).
	/	Jaffe et al., "Culture of Human Endothelial Cells Derived from Umbilical Veins," <i>J. of Clin. Invest.</i> , 1973, 52:2745-2756
	/	Kerr, Janet S. et al., "Novel Small Molecule α v Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors," <i>Anticancer Research</i> , 19:959-968 (1999).
	/	Klagsbrun, M. et al., "Regulators of Angiogenesis," <i>Annu. Rev. Physiol.</i> , 1991, 53:217-32
	/	Klein, S. et al., "Basic Fibroblast Growth Factor Modulates Integrin Expression in Microvascular Endothelial Cells," <i>Mol. Biol. Cell.</i> , 1993, 4:973-82.
	/	Klein, S. et al., "Integrin Regulation by Endogenous Expression of 18-kDa Fibroblast Growth Factor-2," <i>J. Biol. Chem.</i> , 1996, 271:22583-90
	/	Knight et al., "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases," <i>FEBS Let.</i> , 1992, 296, 263-266
	/	Knighton, D.R. et al., "Oxygen Tension Regulates the Expression of Angiogenesis Factor by Macrophages," <i>Science</i> , 1983, 221:1283-85
CHK	/	Koch, A. E. et al., "Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1," <i>Nature</i> , 1995, 376:517-19

EXAMINER

CHK

DATE CONSIDERED

4/30/03

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

Sheet 6 of 9



ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

Crk	Kuettner, K. E. et al., "Tumor Cell Collagenase and Its Inhibition by a Cartilage-Derived Protease Inhibitor," <i>Science</i> , 1977, 196:653-654.
	Laemmli, U.K., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," <i>Nature</i> , 1970, 227:680
	Langer, Robert, Henry Brem, Kenneth Falterman, Michael Klein, Judah Folkman, "Isolation of a Cartilage Factor That Inhibits Tumor Neovascularization," <i>Science</i> , Vol. 193, pp. 70-72.
	Laue, Thomas M. et al., "Guide to Protein Purification," <i>Methods in Enzymology</i> , 1990, 182:566-587
	Lee, Anne and Robert Langer, "Shark Cartilage Contains Inhibitors of Tumor Angiogenesis," <i>Science</i> , Vol. 221, pp. 1186-1187.
	Luer, C. A., "Inhibitors of Angiogenesis from Shark Cartilage," <i>Fed. Proc.</i> 45(4): 949.
	Marquart, FX et al., "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-CU2+ in rat experimental wounds," <i>J Clin Invest</i> , 92(5):2368-76, (Nov. 1993).
	Mathews, James, "Media Feeds Frenzy Over Shark Cartilage As Cancer Treatment," <i>Journal of the National Cancer Institute</i> , Vol. 85, No. 15, August 4, 1993, p. 1190.
	Matsui, M.S. et al. (1992), "Protein Kinase C in Normal Human Epidermal Keratinocytes During Proliferation and Calcium-Induced Differentiation," <i>J. Invest. Dermatol.</i> 99: 565-571.
	Mazure, N. M. et al., "Oncogenic Transformation and Hypoxia Synergistically Act to Modulate Vascular Endothelial Growth Factor Expression," <i>Cancer Res.</i> , 1996, 56:3436-40
	McGuire, Timothy R., Peter W. Kazakoff, Eric B. Hoie, and Margery A. Fienhold, "Antiproliferative Activity of Shark Cartilage With and Without Tumor Necrosis Factor- α in Human Umbilical Vein Endothelium," <i>Pharmacotherapy</i> , 1996;16(2), p. 237.
	Medina, D. and K. B. DeOME (1969), "Response of Hyperplastic Aveolar Nodule Outgrowth-Line D1 to Mammary Tumor Virus, Nodule-Inducing Virus, and Prolonged ..." <i>J. Natl. Cancer Inst.</i> 42: 303-310.
	Medina (1976), "Mammary Tumorigenesis in Chemical Carcinogen-Treated Mice. VI. Tumor-Producing Capabilities of Mammary Dysplasias in BALB/cCrgl Mice," <i>J. Natl. Cancer Inst.</i> Vol. 57, No. 5, pp. 1185-1189.
	Mignatti, P. et al., "Expression of the Urokinase Receptor in Vascular Endothelial Cells Is Stimulated by Basic Fibroblast Growth Factor," <i>J. Cell. Biol.</i> , 1994, 113:1193-201
	Morales, T. I., K. E. Kuettner, D. S. Howell and J. F. Woessner, "Characterization of the Metalloproteinase Inhibitor Produced by Bovine Articular Chondrocyte Cultures," <i>Biochimic et Biophysica Acta</i> , 760 (1983), p. 221-229.
	Moses, Marsha A. and Robert Langer, "Inhibitors of Angiogenesis," <i>Biotech</i> 1991; 9:, pp. 630-634.
	Moses, Marsha A., Judith Sudhalter and Robert Langer, "Identification of an Inhibitor of Neovascularization from Cartilage," <i>Science</i> , Vol. 248, pp. 1408-1410.
	Moses, Marsha A. and Robert Langer, "A Metalloproteinase Inhibitor as an Inhibitor of Neovascularization," <i>Journal of Cellular Biochemistry</i> , Vol. 47, 1991, pp. 230-235.
Crk	Moses, M. A., "A Cartilage-Derived Inhibitor of Neovascularization and Metalloproteases," <i>Clinical and Experimental Rheumatology</i> 11 (Supp. 8), 1993, p. S67-S69.

EXAMINER

DATE CONSIDERED


EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

Sheet 7 of 9



ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CHK	/	Moses, Marsha A. and Robert Langer, "Metalloproteinase Inhibition as a Mechanism for the Inhibition of Angiogenesis," <i>Angiogenesis: Key Principles - Science - Technology - Medicine</i> , 1992, pp. 146-151.
/	/	Moses, M. A. et al., "The Role of Growth Factors in Vascular Cell Development and Differentiation," <i>Int. Rev. Cytol.</i> , 1995, 161:1-48
/	/	Nickoloff, B. J. et al. (1994), "Aberrant Production of Interleukin-8 and Thrombospondin-1 Psoriatic Keratinocytes Mediates Angiogenesis," <i>Am. J. Pathology</i> 144(4): 820-828.
/	/	Oikawa, T., H. Ashino-Fuse, M. Shimamura, U. Koide and T. Kwaguchi, "A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis," <i>Cancer Letters</i> , 51 (1990) 181-186.
/	/	Oresajo, C. et al. (1987), "Eye Area Problems Puffiness, Bags, Dark Circles and Crowsfeet," <i>Cosmetics and Toiletries</i> 102:29-34.
/	/	Passaniti, Antonino et al., "Methods in Laboratory Investigation: A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> , 67:4, 519-528 (1992).
/	/	Paull, Bendicht U., Vincent A. Memoll, and Klaus E. Kuettner, "Regulation of Tumor Invasion by Cartilage-Derived Anti-Invasion Factor in Vitro," <i>JNCI</i> , Vol. 67, No. 1, July 1981, pp. 65-73.
/	/	Pavia et al., "Introduction to Organic Laboratory Techniques a Contemporary Approach," 2nd Ed., Saunders College Publishing, Philadelphia, pages 500-501.
/	/	Pepper, M. S. et al., "Basic Fibroblast Growth Factor Increases Junctional Communication and Connexin 43 Expression in Microvascular Endothelial Cells," <i>J. Cell Physiol.</i> , 1992, 152:196-205
/	/	Pepper, M. S. et al., "Potent Synergism between Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in the Induction of Angiogenesis in Vitro," <i>Biochem. Biophys. Res. Commun.</i> , 1992, 189:824-31
/	/	Pinnagoda (1990), "Guidelines for transepidermal water loss (TEWL) measurement," <i>Contact Dermatitis</i> 22: 164-178.
/	/	Pluda, James M., "Tumor-Associated Angiogenesis: Mechanisms, Clinical Implications, and Therapeutic Strategies," <i>Seminars in Oncology</i> , 24:2, 202-218 (April 1997).
/	/	Polverini, P. J., "How the Extracellular Matrix and Macrophages Contribute to Angiogenesis-dependent Diseases," <i>Eur. J. Cancer</i> , 1996, 32A:2430-7
/	/	Proost, P. et al., "The role of chemokines in inflammation," <i>Int. J. Clin. Lab. Res.</i> , 1996, 26:211-23
/	/	Raju, KS et al., "Characterization of a chemoattractant for endothelium induced by angiogenesis effectors," <i>Cancer Res.</i> , 44(4): 1579-84 (Apr. 1984).
/	/	Raju, KS et al., "Ceruloplasmin, Copper Ions, and Angiogenesis," <i>JNCI</i> , 69:1183-1188 (1982).
/	/	Rak, J. et al., "Reciprocal Paracrine Interactions Between Tumour Cells and Endothelial Cells: the 'Angiogenesis Progression' Hypothesis," <i>Eur. J. Cancer</i> , 1996, 32A:2438-50
CHK	/	Rak, J. et al., "Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls," <i>Cancer and Metastasis Reviews</i> 15:231-236 (1996).

EXAMINER

CHK

DATE CONSIDERED

4/30/03


EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

Sheet 8 of 9



ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CHK	/	Rak, J. E. et al., "Progressive Loss of Sensitivity to Endothelium-Derived Growth Inhibitors Expressed by Human Melanoma Cells During Disease Progression," <i>J. Cell Physiol.</i> , 1994, 159:245-55
	/	Raza, SL et al., "Matrix metalloproteinases: pro- and anti-angiogenic activities," <i>J Investig Dermatol Symp Proc</i> , 5(1):47-54 (Dec. 2000).
	/	Ritchie, Boyle, McInnes, Jasani, Dalakos, Grieson and Buchanan (1968), "Clinical Studies with an Articular Index for the Assessment of Joint Tenderness in Patients with Rheumatoid Arthritis," <i>Quarterly Journal of Medicine, New Series XXXVII</i> , No. 147, pp. 393-407.
	/	Rosen and Woodhead, "High Ionic Strength: Its Significance in Immunosurveillance Against Tumor Cells in Sharks and Rays (Elasmobranchs)," <i>Medical Hypotheses</i> , 1980, 6:441-446
	/	Sadove, Alan Michael, MD, MS and Klaus E. Kuettner, Ph.D., "Inhibition of Mammary Carcinoma Invasiveness with Cartilage-Derived Inhibitor," <i>Orthopaedic Surgery</i> , pp. 499-501.
	/	Sage, EH et al., "Regulation of angiogenesis by extracellular matrix: the growth and the glue," <i>J Hypertens Suppl</i> , 12(10):S145-52 (Dec. 1994).
	/	Sandner, P. et al., "Induction of VEGF and VEGF receptor gene expression by hypoxia: Divergent regulation <i>in vivo</i> and <i>in vitro</i> ," <i>Kidney Int.</i> , 1997, 51:448-53
	/	Sauder, Daniel N. et al., "Angiogenesis in Dermatology," <i>Curr Prob Dermacol</i> , 1-10 (May/June 2001).
	/	Schwartz, S. M. et al., "Growth Control and Morphogenesis in the Development and Pathology of Arteries," <i>J. Cardiovasc. Pharmacol.</i> , 1993, 21 Suppl. 1:S31-S49
	/	Schweigerer, L. et al., "Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth," <i>Nature</i> , 1987, 325:258-9
	/	Scott et al., "Selective Demineralization of Hard Tissues in Organic Solvents: Retention or Extraction of Proteoglycan?", <i>J. Microsc.</i> , 134(3), pages 291-297.
	/	Sheu, Fu, Tsai and Chung, "Effect of U-995, a Potent Shark Cartilage-Derived Angiogenesis Inhibitor, on Anti-Angiogenesis and Anti-Tumor Activities," <i>Abtucabcer Research</i> 18L 4435-4442 (1998).
	/	Siemeister, Gerhard et al., "Two Independent Mechanisms Essential for Tumor angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering with either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," <i>Cancer Research</i> 59, 3185-3191 (July 1, 1999).
	/	Simeon, A. et al., "Expression and activation of matrix metalloproteinases in wounds: modulations by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-CU2+," <i>J Invest Dermatol</i> , 112(6):957-64 (June 1999).
	/	Skobe, M. et al., "Halting angiogenesis suppresses carcinoma cell invasion," <i>Nature Medicine</i> , Vol. 3(11): 1222-1228 (1997).
	/	Sorgente, N. et al., "The Resistance of Certain Tissues to Invasion," <i>Laboratory Investigation</i> , Vol. 32, No. 2, p. 217 (1975).
	/	Suzuki, Fujio, Masaharu Takigawa, Yugi Hiraki, Yukio Kato, Keisuke Fukuo, Tsuyoshi Shiio and Yasumi Yugari, "Cartilage-derived Antitumor Factor (CATF): A High Molecular Weight Fraction Cartilage Extract Inhibits Solid Tumor Growth," <i>Journal of Bone and Mineral Metabolism</i> , 1984 Vol. 2 No. 3, pp. 53-57.
CHK	/	Takano, Shingo et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients," <i>Cancer Research</i> 56, 2185-2190 (May 1996).

EXAMINER

CHK

DATE CONSIDERED

4/30/03


EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

Sheet 9 of 9



ATT. DOCKET NO.

014985-0012-72648

SERIAL NO.

09/879,660

APPLICANT: DUPONT ET AL.

FILING DATE: June 12, 2001

GROUP:

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CMK ✓	Tolnay, E. et al., "Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 123:652-658 (1997).
✓	Weber, G., "Biochemical Strategy of Cancer Cells and the Design of Chemotherapy: G. H. A. Clowes Memorial Lecture," <i>Cancer Research</i> , 43: 3466-3492 (August 1983).
✓	Weingarten, Martin and Feder (1985), "Synthetic Substrates of Vertebrate Collagenase," <i>Biochemistry</i> 24, 6730-6734.
✓	Welgus et al., "The Collagen Substrate Specificity of Human Skin Fibroblast Collagenase," <i>J. Biol. Chem.</i> , 1979, 256:9511-9516
CMK ✓	Wilkin, J. K., "Rosacea," <i>Arch. Dermatol.</i> , 1994, vol. 130, 359-362

EXAMINER

Chen

DATE CONSIDERED

4/30/03

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

#480063